Cytosorbents Corporation
CTSO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $59 | $80 | $61 | $50 |
| - Cash | $8 | $10 | $12 | $3 |
| + Debt | $27 | $27 | $27 | $27 |
| Enterprise Value | $78 | $97 | $76 | $73 |
| Revenue | $9 | $10 | $9 | $9 |
| % Growth | -1.4% | 10.2% | -4.6% | – |
| Gross Profit | $7 | $7 | $6 | $9 |
| % Margin | 70.3% | 70.9% | 71.1% | 102.7% |
| EBITDA | -$3 | -$3 | -$4 | -$9 |
| % Margin | -30.8% | -33.4% | -40.3% | -93.2% |
| Net Income | -$3 | $2 | -$1 | -$8 |
| % Margin | -33.4% | 20.2% | -16.9% | -86.2% |
| EPS Diluted | -0.05 | 0.029 | -0.024 | -0.14 |
| % Growth | -272.4% | 219.3% | 82.6% | – |
| Operating Cash Flow | – | -$2 | -$3 | -$2 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$2 | -$4 | -$2 |